EchoGo® Amyloidosis
Detection of Cardiac Amyloidosis
ApprovedActive
Key Facts
About Ultromics
Ultromics is a private, commercial-stage diagnostics company leveraging AI to transform echocardiography analysis. Its core product, the cloud-based EchoGo® platform, hosts FDA-cleared medical devices that assist in the detection of HFpEF and cardiac amyloidosis, addressing significant unmet needs in cardiology. Founded in 2017 as a spin-out from the University of Oxford, the company has established key partnerships with institutions like the Mayo Clinic, secured reimbursement pathways, and processed over 430,000 clinical cases. Ultromics is positioned at the intersection of AI, cardiology, and digital health, with a clear focus on scaling its validated technology across healthcare systems.
View full company profile